SCHEMBL5065400

SCHEMBL5065400

CSc1ncnc2sc(-c3ccc(F)cc3)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 7/20 0.44
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CB P42338 1/20 0.43
PIK3CG P48736 1/20 0.43
CHUK O15111 5/20 0.43
APP P05067 4/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MAOB P27338 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MEN1 O00255 1/20 0.36
MITF O75030 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
STAT3 P40763 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1693615 0.86 PIK3CD (0.43) IKBKBPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5064776 0.84 ADORA3 (0.50) MITFHTTPAX8PIP4K2C
SCHEMBL5064310 0.83 PIK3CD (0.42) IKBKBPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5064152 0.81 PIK3CD (0.40) IKBKBPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL654971 0.80 ADORA3 (0.47) IKBKBCHUKAPPMAOBALOX5
SCHEMBL654572 0.80 IKBKB (0.44) IKBKBCHUKAPPALDH1A1MAOB
SCHEMBL654696 0.79 IKBKB (0.49) IKBKBCHUKAPPMAOB
SCHEMBL14031859 0.77 PIK3CD (0.37) IKBKBPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5064698 0.76 PIK3CD (0.38) IKBKBPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL5064749 0.75 MAPT (0.49) LMNAALDH1A1CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269238-A1 Thiazolopyrimidine Derivative FGFR3, FGFR1, ERBB3 IKBKB 1604/4885PIK3CD 3788/4885PIK3CA 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.